PGEN

7.75

0.65% 0.05

Dopo l'orario di chiusura: 7.78 0.03 +0.39%

Precigen Inc (PGEN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$7.70

Aprire:

$8.08

Volume 24 ore:

6.56M

Relative Volume:

1.31

Capitalizzazione di mercato:

$2.77B

Reddito:

$9.68M

Utile/perdita netta:

$-250.64M

Rapporto P/E:

-5.5365

EPS:

-1.3998

Flusso di cassa netto:

$-89.83M

1 W Prestazione:

-0.39%

1M Prestazione:

+6.46%

6M Prestazione:

+150.00%

1 anno Prestazione:

+122.38%

Intervallo 1D:

$7.63

$8.27

Intervallo di 1 settimana:

$7.19

$8.27

Portata 52W:

$2.99

$8.27

Precigen Inc Stock (PGEN) Company Profile

Nome

Precigen Inc

Settore

Healthcare (1067)

Industria

Biotechnology (595)

Telefono

301-556-9900

Indirizzo

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Dipendente

Cinguettio

@precigen

Prossima data di guadagno

2026-11-12

Ultimi documenti SEC

PGEN's Discussions on Twitter

Compare PGEN vs VRTX, REGN, MRNA, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PGEN Precigen Inc	7.75	2.77B	9.68M	-250.64M	-89.83M	-1.3998
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-15	Aggiornamento	JP Morgan	Underweight → Neutral
2024-03-22	Downgrade	JP Morgan	Neutral → Underweight
2023-05-23	Iniziato	JP Morgan	Neutral
2022-11-18	Iniziato	Cantor Fitzgerald	Overweight
2021-02-25	Iniziato	Stifel	Buy
2021-02-22	Iniziato	Wells Fargo	Overweight
2021-02-18	Iniziato	B. Riley Securities	Buy
2020-05-08	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Precigen Inc Borsa (PGEN) Ultime notizie

01:09 AM

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap? - Yahoo Finance

01:09 AM

Sep 25, 2026

MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today? - fr.tradingview.com

Sep 25, 2026

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies - Yahoo Finance

Sep 25, 2026

B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target - TradingView

Sep 25, 2026

B.Riley initiates Precigen stock coverage with buy on drug launch By Investing.com - Investing.com South Africa

Sep 25, 2026

Precigen Initiated at Buy by B. Riley Securities - Moomoo

Sep 25, 2026

Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

B.Riley initiates Precigen stock coverage with buy on drug launch - Investing.com Canada

Sep 25, 2026

Form 4 Precigen Inc For: 25 September - Investing.com India

Sep 25, 2026

Sep 24, 2026

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? - uk.finance.yahoo.com

Sep 24, 2026

Sep 23, 2026

Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research

Sep 23, 2026

Sep 21, 2026

Precigen's AdenoVerse Receives FDA Platform Technology Designation - marketscreener.com

Sep 21, 2026

PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Chal - GuruFocus

Sep 21, 2026

FDA grants platform technology status to Precigen’s AdenoVerse - Investing.com

Sep 21, 2026

September 2026's Leading Growth Companies With Insider Backing - simplywall.st

Sep 21, 2026

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform - TradingView

Sep 21, 2026

Sep 18, 2026

Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base - Yahoo Finance

Sep 18, 2026